ライフサイエンスコーパス: intensive insulin therapy

1 ed awareness of hypoglycemia while receiving intensive insulin therapy.

2 or a minimum of 12 months who were receiving intensive insulin therapy.

3 ll pregnant women with type 1 diabetes using intensive insulin therapy.

4 nsulin therapy as compared with a decline in intensive insulin therapy.

5 rrection uncovers occult hypoglycemia during intensive insulin therapy.

6 educes the prevalence of hypoglycemia during intensive insulin therapy.

7 rom recurrent hypoglycemia in patients using intensive insulin therapy.

8 re from critically ill patients who received intensive insulin therapy.

9 r breakdown, that follows the institution of intensive insulin therapy.

10 rregulation seen in diabetic patients during intensive insulin therapy.

11 as a basal insulin to increase the safety of intensive insulin therapy.

12 answer to the question about the effects of intensive insulin therapy.

13 orable outcome, which enhances the safety of intensive insulin therapy.

14 een slower and is focused on those receiving intensive insulin therapy.

15 de-1 (1.5 pmol/kg/min) or normal saline plus intensive insulin therapy.

16 ation of palmitate significantly improved in intensive insulin therapy (0.9 +/- 0.1 to 1.7 +/- 0.1 mi

17 ose release was significantly greater in the intensive insulin therapy after treatment compared with

18 n more efficacious, at least initially, with intensive insulin therapy and may justify setting a high

19 ic porcine islets could be an alternative to intensive insulin therapy and pancreatic transplantation

20 The rationale for intensive insulin therapy and results from major clinica

21 However, the extent to which intensive insulin therapy and tight control of blood glu

22 into two groups receiving either standard or intensive insulin therapy and were followed for 27 month

23 irected therapy, drotrecogin alfa, steroids, intensive insulin therapy, and lung-protective ventilati

24 Intensive insulin therapy, and specifically insulin pump

25 r breakdown is markedly increased with acute intensive insulin therapy but can be reversed by treatin

26 ficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabete

27 tive glycemic control could be achieved with intensive insulin therapy, but no effect on vascular end

28 Muscle atrophy was not ameliorated by intensive insulin therapy, but possibly aggravated by co

29 Clinical studies have demonstrated that intensive insulin therapy causes a transient worsening o

30 wer plasma glucose levels, particularly with intensive insulin therapy, could therefore be harmful.

31 (HbA(1c) 10.1%) and again after 3 months of intensive insulin therapy designed to produce near-normo

32 Intensive insulin therapy displayed a significantly high

33 Intensive insulin therapy during cardiac surgery does no

34 Tight glycemic control by intensive insulin therapy effectively delays the onset a

35 Intensive insulin therapy for tight glycemic control in

36 oglycemia is the most feared complication of intensive insulin therapy for type 1 diabetes.

37 s needed to assess the benefit:risk ratio of intensive insulin therapy for type II diabetic patients

38 Intensive insulin therapy has improved outcomes in some,

39 Despite demonstrated benefits, intensive insulin therapy has not gained widespread clin

40 0 mg/dl) improves patient survival; however, intensive insulin therapy (IIT) targeting normal blood g

41 The benefits and harms of intensive insulin therapy (IIT) titrated to strict glyce

42 tive Study explored the feasibility of using intensive insulin therapy in 153 male type II diabetic p

43 Hypoglycemia occurs frequently during intensive insulin therapy in patients with both type 1 a

44 Intensive insulin therapy in the critically ill reduces

45 ring on interpretation of previous trials of intensive insulin therapy in the critically ill.

46 The reduced mortality observed with intensive insulin therapy in the Leuven trials cannot be

47 inical problem is the question of the use of intensive insulin therapy in type II diabetic individual

48 Acute intensive insulin therapy is an independent risk factor

49 has been shown to reduce mortality; however, intensive insulin therapy is associated with iatrogenic

50 al antibiotics, early goal-directed therapy, intensive insulin therapy, lung-protective ventilation,

51 Intensive insulin therapy maintained blood glucose level

52 Here we demonstrate that acute intensive insulin therapy markedly increases VEGF mRNA a

53 Early data from the UKPDS also suggest that intensive insulin therapy may be more effective in lower

54 Intensive insulin therapy may cause a transient worsenin

55 Intensive insulin therapy may impair cerebral glucose me

56 oose insulin (n=33) for the initial 2 yrs or intensive insulin therapy (n=14) for the last year.

57 Intensive insulin therapy normalizes glycemia by decreas

58 We evaluated the effects of prior intensive insulin therapy on the prevalence and incidenc

59 insulin therapy vs. 6.8 +/- 0.9 mg/kg x min intensive insulin therapy; p = .5).

60 together, these findings indicate that acute intensive insulin therapy produces a transient worsening

61 Intensive insulin therapy promises to reduce health risk

62 lood glucose levels < or =120 mg/dL using an intensive insulin therapy protocol improves insulin sens

63 especially among patients with T2D not using intensive insulin therapy, remains limited.

64 Intensive insulin therapy results in a net reduction in

65 Intensive insulin therapy significantly lowered mean blo

66 The Leuven intensive insulin therapy strategy increased mean daily

67 Intensive insulin therapy (systemic glucose target: 4.4-

68 , patients were randomized to receive either intensive insulin therapy (targeting normoglycemia, betw

69 s more likely to produce hypoglycemia during intensive insulin therapy than is total parenteral nutri

70 In 14 patients treated with intensive insulin therapy, there was a reduction in micr

71 the evidence for the link between the use of intensive insulin therapy to achieve different glycemic

72 RECOMMENDATION 2: ACP recommends not using intensive insulin therapy to normalize blood glucose in

73 Intensive insulin therapy to normalize blood glucose may

74 xperts calling for routine administration of intensive insulin therapy to normalize glucose levels in

75 RECOMMENDATION 1: ACP recommends not using intensive insulin therapy to strictly control blood gluc

76 amp infusion rate posttreatment (9.1 +/- 1.3 intensive insulin therapy versus 4.8 +/- 0.6 mg/kg x min

77 py (5.0 +/- 0.9 vs. 2.5 +/- 0.6 mg/kg x min; intensive insulin therapy vs. conventional insulin thera

78 However, intensive insulin therapy was associated with increased

79 Intensive insulin therapy was done using a stepwise appr

80 nd Complications Trial (DCCT) has shown that intensive insulin therapy will prevent or delay the onse

81 Intensive insulin therapy with IIP and MDI is effective

82 nduction, islet culture, heparinization, and intensive insulin therapy with the same low-dose tacroli

83 Intensive insulin therapy with tight glycaemic control h

84 nuous infusion of glucagon-like peptide-1 to intensive insulin therapy would result in better glucose